CLEC10A, (C‐type lectin domain family 10, member A), as the member of C‐type lectin receptors (CLRs), plays a vital role in modulating innate immunity and adaptive immunity and has shown great potential as an immunotherapy target for cancers. Here, CLEC10A is linked to cancer.